lobbying_activities: 2340935

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2340935	342d36e3-73ba-4521-b954-8b883435e4d5	Q3	RED+BLUE STRATEGIES	400693064	PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)	2019	third_quarter	MMM	H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. Legislative policies and reforms related to Medicare Part B and D specific to the price of prescription medications. C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.	HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2019-10-13T09:10:22.420000-04:00